-
公开(公告)号：US20220324863A1
公开(公告)日：2022-10-13
申请号：US17744432
申请日：2022-05-13
Applicant: NOVARTIS AG
Inventor： Jan Jiricek , Isabelle K. Lerario , Fang Liang , Xiaodong Liu , Valentina Molteni , Advait Suresh Nagle , Shuyi Pearly NG , Maxim Ratnikov , Jeffrey M. Smith , Yongping Xie
IPC: C07D471/04 , A61P33/02 , C07D519/00
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20160263113A1
公开(公告)日：2016-09-15
申请号：US15070905
申请日：2016-03-15
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: A61K31/506 , A61K31/4184
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US20160280687A1
公开(公告)日：2016-09-29
申请号：US15179644
申请日：2016-06-10
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04 , C07D401/14 , C07D405/14
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
Patent Agency Ranking
公开(公告)号：US20160280686A1
公开(公告)日：2016-09-29
申请号：US15179385
申请日：2016-06-10
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04 , C07D405/14 , C07D401/14
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US20160122324A1
公开(公告)日：2016-05-05
申请号：US14994710
申请日：2016-01-13
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US09314464B2
公开(公告)日：2016-04-19
申请号：US13931111
申请日：2013-06-28
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: A61K31/535 , A61K31/506 , C07D401/14 , C07D403/04 , A61K45/06 , C07D405/14
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US11384078B2
公开(公告)日：2022-07-12
申请号：US16615749
申请日：2018-05-29
Applicant: NOVARTIS AG
Inventor： Jan Jiricek , Isabelle K. Lerario , Fang Liang , Xiaodong Liu , Valentina Molteni , Advait Suresh Nagle , Shuyi Pearly Ng , Maxim Ratnikov , Jeffrey M. Smith , Yongping Xie
IPC: A61K31/7048 , A61K31/541 , A61K31/197 , A61K31/155 , A61K31/555 , A61K31/417 , C07D519/00 , C07D471/04 , C07D487/04 , A61P33/02
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20160120866A1
公开(公告)日：2016-05-05
申请号：US14994827
申请日：2016-01-13
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: A61K31/506 , A61K31/4184 , A61K9/00
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
